Trade
Basic
Futures
Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
More
Lilly to launch multi-dose weight-loss drug device in US
Lilly to launch multi-dose weight-loss drug device in US
Reuters
Mon, February 23, 2026 at 11:03 PM GMT+9 1 min read
In this article:
LLY
+3.31%
Feb 23 (Reuters) - Eli Lilly said on Monday it received the U.S. Food and Drug Administration’s approval to launch a four-dose KwikPen for its weight-loss drug Zepbound, delivering a full month of the treatment in a single device.
Rival Novo Nordisk’s Wegovy has been sold as a single-dose weekly autoinjector pen for weight loss in the U.S. since 2021.
NYSE - Nasdaq Real Time Price • USD
(LLY)
1,042.98 +33.46 (+3.31%)
As of 9:49:45 AM EST. Market Open.
Advanced Chart
Here are some details:
Zepbound KwikPen will be available starting at $299 per month for the 2.5-milligram dose for cash-paying customers
The multi-dose injection pen will be available in all six doses - 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg
KwikPen is also used to deliver Lilly’s diabetes drug Mounjaro
The device is available in many major international regions such as the United Kingdom, Australia, the Middle East and Canada
Zepbound, approved by the FDA in 2023, is also available as a single-dose autoinjector or in vials in the U.S.
It has overtaken Novo Nordisk’s Wegovy as the weight-loss market leader in the U.S., based on prescription data
(Reporting by Christy Santhosh in Bengaluru; Editing by Sriraj Kalluvila)
Terms and Privacy Policy
Privacy Dashboard
More Info